Orrick's Life Sciences team explores how the healthcare industry is bracing for significant developments in regulation and litigation in a recent ...

The health care industry has used AI for decades, but the rise of generative AI raises questions about how to regulate the technology.

Proposed AI legislation in California may have big implications in health care.

Though responsible and ethical use of artificial intelligence (AI) has been a hot topic for the past few years, there has not yet been significant ...

What should public life sciences companies should know about expansive new theories of liability in two insider trading cases?

Federal agencies and lawmakers in several states are attempting to rewrite the rulebook for private investment in health care in the U.S.

The FTC has updated its Health Breach Notification Rule that applies to non-HIPAA, consumer health data. The updated rule applies to vendors of ...

U.S. antitrust enforcers launched initiatives in 2024 to identify and prevent antitrust and other violations in life sciences and health care.

The Supreme Court should reverse a decision on statutory patent term guarantees for Patent Office delays, Orrick’s Irena Royzman and Lauren Drake say.

The Department of HHS has issued a final rule updating the HIPAA Privacy Rule in an effort to better protect data related to reproductive health.

The U.S. Department of Health & Human Services issued a final rule updating the Confidentiality of Substance Use Disorder Patient Records regulations.

Reverse mergers have helped biotech companies access public markets, but recent SEC positions are threatening that path to going public.